Opinion|Videos|February 11, 2025
BCG-Unresponsive NMIBC: Balancing Care and Financial Considerations
Author(s)Mark D. Tyson, II, MD, MPH
A panelist discusses how treatment decisions for BCG-unresponsive non–muscle-invasive bladder cancer (NMIBC) involve careful consideration of patient preferences, long-term cost-effectiveness, and available financial assistance programs, balancing the higher upfront costs of newer therapies with their potential economic benefits from reduced recurrence rates and treatment frequency.
Advertisement
Episodes in this series
- What is your approach to discussing treatment options with patients, especially when considering the long-term financial impact of different therapies?
- With all the available treatments on the market, what are your patient preferences when it comes to treatment experiences?
- Annual cost analyses suggest that some newer therapies may have higher upfront costs but can be more economical in the long run due to fewer recurrences and less frequent administration.
- How does the cost-effectiveness of treatments, particularly in relation to newer therapies, influence your recommendations for patients with BCG-unresponsive NMIBC?
- Are there specific tools or resources you rely on to help assess and present these options to patients?
- What financial assistance or patient support programs (eg, co-pay cards, patient assistance foundations, or programs) have you found most helpful in ensuring patients can afford and access the right treatments, and how do you guide patients in utilizing these resources?
Newsletter
Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
FDA grants clearance to Hugo robotic-assisted surgery system for urologic procedures
2
Apalutamide is linked to fewer CNS-related conditions in patients with nmCRPC
3
Prostate MRI is linked with higher sensitivity, NPV vs micro-ultrasound in pilot study
4
BOND-003: Cretostimogene yields durable 24-month responses in high-grade NMIBC
5
